TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01266798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal
Description: The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation
Study: NCT03348657

Intervention type: OTHER
Group type: OTHER
Intervention: Music Session
Description: Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
Study: NCT02184416

Intervention type: OTHER
Intervention: observational
Description: The study is non interventional. All drugs will be prescribed
Study: NCT01825863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 9%
Study: NCT02830789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet manufactured to mimic a calcium carbonate tablet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
Study: NCT00449852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response
Description: The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
Study: NCT02554474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, Fitbit/FitViz, physiotherapist counselling.
Description: Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 9-week delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
Study: NCT01949454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears (Placebo)
Description: Artificial tears (Placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears (Placebo)
Description: Artificial tears (Placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears (Placebo)
Description: Artificial tears (Placebo)
Study: NCT01821872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of paracetamol
Description: Administration of 1g intravenous paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of paracetamol
Description: Administration of 1g intravenous paracetamol
Study: NCT02830789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
Study: NCT01398787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
Study: NCT01228383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies virus-specific monoclonal antibodies
Description: CL184 20 IU/kg intramuscularly on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies virus-specific monoclonal antibodies
Description: CL184 20 IU/kg intramuscularly on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human polyclonal rabies immune globulin (HRIG)
Description: HRIG 20 IU/kg intramuscularly on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intramuscularly on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intramuscularly on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell vaccine (HDCV)
Description: Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human diploid cell vaccine (HDCV)
Description: Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
Study: NCT00696293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine up to 120 mg/day + Clinical Management
Study: NCT05146011

Intervention type: PROCEDURE
Intervention: Gatsric balloon insertion
Description: Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery

Intervention type: PROCEDURE
Intervention: Gatsric balloon insertion
Description: Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
Study: NCT03398356

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.
Study: NCT02362113

Intervention type: OTHER
Intervention: GI/GL
Description: GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
Study: NCT00740285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% without vessel constrictor
Description: * first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - physiological solution 0,9%
Description: first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
Study: NCT00170235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Exercise class pre-surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Exercise booklet, physiotherapy if needed
Study: NCT03405181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with additional weight
Description: The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training without additional weight
Description: The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
Study: NCT02412761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
Study: NCT01821872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of paracetamol
Description: Administration of 1g intravenous paracetamol
Study: NCT02594943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Large Capacity with needle Biopsy
Description: The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endodrill 1A (BIBBInstruments, Lund, Sweden)
Description: The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
Study: NCT02770365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace cream (Perrigo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estrace cream (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study: NCT01848457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate infusion duration
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
Study: NCT02412761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
Study: NCT01677039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation administered with water
Description: single dose of 20 mg of test formulation with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation administered with 20% ethanol
Description: single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation administered with 40% ethanol
Description: single dose of 20 mg of test formulation with 240 mL of 40% ethanol
Study: NCT05535036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: all patients had standard non-invasive monitoring including an electrocardiogram, non invasive blood pressure and pulse oxymetry. An 18-gauge intravenous cannula was inserted into the nondominant arm or hand and 500 ml of a saline solution (0.9 %) was infused. The prevention of postoperative nausea and vomiting (PONV) was assured to all patients by administering 4 mg of IV Ondansetron. Spinal anesthesia was performed according to our department protocol: L4-L5 or L3-L4 intervertebral space puncture using a 25 gauges needle, with injection of 0.5% hyperbaric Bupivacaine mixture (dose depending on patient height) associated with 2.5 ug Sufentanil and 100 ug Morphine. Before surgical incision, patients received either an intravenous injection of 8 mg (2 ml) Dexamethasone (DG) or 2 ml of a Saline solution (PG).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients received 2ml of intravenous saline solution
Study: NCT01848457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate infusion duration
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate infusion duration
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate infusion duration
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
Study: NCT02436486

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ldalopirdine 120 mg
Description: Two 60 mg encapsulated film-coated tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 360 mg
Description: Four 90 mg encapsulated film-coated tablets, orally, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Encapsulated tablets, orally, single dose
Study: NCT05553756

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: 200 ml maltodextrin given 2 hours before cesarean section
Study: NCT03067662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study: NCT02084134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: 100mg at the time of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 0.5mg every 6 hours for a total of four doses
Study: NCT04892862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH
Description: ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH
Description: ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
Study: NCT01010841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UltraMealPlus 360 (Medical food)
Description: Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-glycemic-load diet
Description: Modified Mediterranean-style low-glycemic-load diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Description: Modified Mediterranean-style low-glycemic-load diet
Study: NCT02664285

Intervention type: OTHER
Group type: OTHER
Intervention: closure of subcutaneous tissue
Description: the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.

Intervention type: OTHER
Group type: OTHER
Intervention: No closure of subcutaneous tissue
Description: the subcutaneous fat will not sutured after cesarean section in diabetic patients.